Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Revenue growth
Regeneron Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 June 2026 was 9.29%, up 8.3 percentage points from fiscal 2025 (0.99%). Over the past ten years it has ranged from −24.3% (fiscal 2022) to 89.1% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of 5.64% and above the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 0.99% | (7.28) |
| FY2024 | 8.27% | 0.51 |
| FY2023 | 7.76% | 32.02 |
| FY2022 | −24.3% | (113.40) |
| FY2021 | 89.1% | 59.56 |
| FY2020 | 29.6% | 2.14 |
| FY2019 | 27.4% | 39.81 |
| FY2018 | −12.4% | (33.19) |
| FY2017 | 20.8% | 2.38 |
| FY2016 | 18.4% | (27.11) |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 16.7% | (2.31) |
| Mar 2026 | 19.0% | 16.53 |
| Dec 2025 | 2.51% | 1.61 |
| Sep 2025 | 0.90% | (2.72) |
| 42 more quarters | Free account |
Against its own ten years
Low −24.3%
High 89.1%
Ten-year median
18.4%
Current reading's percentile
27
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 185.8% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 95.1% |
| ARGX argenex SE compare | 70.6% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 34.4% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.2% |
| RPRX Royalty Pharma PLC compare | 10.0% |
| REGN Regeneron Pharmaceuticals, Inc. | 9.29% |
| RVMD Revolution Medicines, Inc. compare | −8.81% |
| MRNA Moderna, Inc. compare | −27.6% |
| Biotechnology industry median | 5.64% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement